Your AI-Trained Oncology Knowledge Connection!
Article
This publication includes a summary of data on the treatment of patients with EGFR exon 20 insertions in non–small cell lung cancer (NSCLC) and the rapidly changing landscape of HER2-targeted treatment. Thoracic oncologists, who specialize in the treatment of lung cancer, provide key insights on the current management of uncommon EGFR mutations in NSCLC and the emerging treatment landscape of targeted therapies.
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Cyclosporin Plus Cyclophosphamide Outperforms SOC Therapy in GVHD Prevention
Dr Fathi on the Efficacy and Safety of Ziftomenib in R/R NPM1-Mutant AML
Dr Schetelig on Haploidentical vs Mismatched Transplant Efficacy in AML/ALL/MDS
Dr Dahiya on the Safety Profile of KITE-363 in Relapsed/Refractory B-Cell Lymphoma
2 Commerce Drive
Cranbury, NJ 08512